Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer

Simple Summary There is no established standard second-line chemotherapy after modified FOLFIRINOX for unresectable pancreatic cancer. While gemcitabine plus nab-paclitaxel is often used as second-line chemotherapy after modified FOLFIRINOX, outcomes and prognostic factors of second-line gemcitabine plus nab-paclitaxel have been unclear. This study revealed that median overall survival (OS) and progression-free survival (PFS) of second-line gemcitabine plus nab-paclitaxel were 7.2 months and 3.6 months, respectively. Performance status, modified Glasgow prognostic score, and neutrophil-to-lymphocyte ratio were independently associated with overall survival. Our prognostic model using these parameters classifies patients into the good and poor prognosis groups. Median OS and PFS were longer in the good prognosis group than in the poor prognosis group. Efficacy of second-line gemcitabine plus nab-paclitaxel was notably limited, particularly in the poor prognosis group. Abstract Outcomes and prognostic factors of second-line gemcitabine plus nab-paclitaxel (GnP) after modified FOLFIRINOX (mFFX) for unresectable pancreatic cancer were unclear. We retrospectively analyzed consecutive patients with unresectable pancreatic cancer treated with GnP after first-line mFFX treatment between March 2015 and March 2022 at our hospital. A total of 103 patients were included. Median overall survival (OS) from the start of first-line and second-line treatments was 14.9 months and 7.2 months, respectively. Median progression-free survival (PFS) was 3.6 months. Performance status, modified Glasgow prognostic score, and neutrophil-to-lymphocyte ratio were independently associated with OS. Our prognostic model using these parameters classifies patients into good (n = 70) and poor (n = 33) prognosis groups. Median OS and PFS were longer in the good prognosis group than in the poor prognosis group (OS: 9.3 vs. 3.8 months, p < 0.01; PFS: 4.1 vs. 2.3 months, p < 0.01). Grade 3/4 adverse events were observed in 70.9% of patients, with neutropenia being the most frequent. While GnP as second-line treatment was well-tolerated, efficacy of second-line gemcitabine plus nab-paclitaxel was notably limited, particularly in the poor prognosis group.

[1]  N. Sasahira,et al.  Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer. , 2022, Japanese journal of clinical oncology.

[2]  M. Morimoto,et al.  Nal-IRI/5-FU/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: A single center retrospective study. , 2022, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[3]  E. O’Reilly,et al.  Pancreatic Cancer: A Review. , 2021, JAMA.

[4]  E. Brun,et al.  Second-line palliative chemotherapy, survival, and prognostic factors in patients with advanced pancreatic cancer , 2021, Acta oncologica.

[5]  T. Nishiuchi,et al.  Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy following FOLFIRINOX in Patients with Unresectable Pancreatic Cancer: A Single-Institution, Retrospective Analysis , 2021, Chemotherapy.

[6]  N. Sasahira,et al.  Treatment outcomes of erlotinib plus gemcitabine as late-line chemotherapy in unresectable pancreatic cancer. , 2021, Japanese journal of clinical oncology.

[7]  J. Feliu,et al.  Prognostic factors in advanced pancreatic ductal adenocarcinoma patients-receiving second-line treatment: a single institution experience , 2021, Clinical and Translational Oncology.

[8]  N. Sasahira,et al.  Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancreatic Cancer , 2021, Pancreas.

[9]  H. Lee,et al.  Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial , 2021, Therapeutic advances in medical oncology.

[10]  J. Cheon,et al.  Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis , 2020, Therapeutic advances in medical oncology.

[11]  N. Sasahira,et al.  Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer , 2020, BMC Cancer.

[12]  Mi-Suk Park,et al.  FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study , 2020, World journal of gastrointestinal oncology.

[13]  M. Shimizu,et al.  Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure , 2019, Journal of clinical medicine.

[14]  D. Pezet,et al.  Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study , 2019, Therapeutic advances in gastroenterology.

[15]  P. Maisonneuve,et al.  Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe. , 2019, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[16]  N. Sasahira,et al.  Improvement of Treatment Outcomes for Metastatic Pancreatic Cancer: A Real-world Data Analysis , 2018, In Vivo.

[17]  Hanbo Zhang,et al.  Efficacy and Tolerability of Second‐line Nab‐paclitaxel and Gemcitabine After Failure of First‐line FOLFIRINOX for Advanced Pancreas Cancer: A Single‐institution Experience , 2018, Clinical colorectal cancer.

[18]  N. Sata,et al.  A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer , 2018, Cancer Chemotherapy and Pharmacology.

[19]  B. O'Neil,et al.  Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer. , 2017, Anticancer research.

[20]  H. Zeh,et al.  Gemcitabine/nab-paclitaxel as second-line therapy following FOLFIRINOX in metastatic/advanced pancreatic cancer-retrospective analysis of response. , 2017, Journal of gastrointestinal oncology.

[21]  M. Reni,et al.  Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer , 2016, British Journal of Cancer.

[22]  B. Dörken,et al.  Second-Line Treatment in Pancreatic Cancer Patients: Who Profits?—Results From the CONKO Study Group , 2016, Pancreas.

[23]  Yan-Shen Shan,et al.  Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial , 2016, The Lancet.

[24]  J. Lacy,et al.  Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity , 2015, Experimental Hematology & Oncology.

[25]  F. Bonnetain,et al.  Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort , 2015, British Journal of Cancer.

[26]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[27]  P. Kornprat,et al.  Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer , 2013, British Journal of Cancer.

[28]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[29]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .

[30]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[31]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[32]  C. McArdle,et al.  Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer , 2007, International Journal of Colorectal Disease.